Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer
Public ClinicalTrials.gov record NCT07925268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center Phase 2 Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, single-arm study evaluating the safety and effectiveness of ifinatamab deruxtecan (I-DXd) in adult men with histologic evidence of de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). I-DXd is an investigational antibody-drug conjugate (ADC) designed to target B7-H3, a protein found at high levels on many neuroendocrine prostate cancer cells. After binding to B7-H3, I-DXd delivers an anticancer drug called deruxtecan (DXd) to tumor cells. DXd interferes with an enzyme called topoisomerase I, which is involved in DNA replication and repair. This causes DNA damage that can lead to cancer cell death.
Study identification
- NCT ID
- NCT07925268
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Interventions
- Ifinatamab Deruxtecan Drug
- Positron Emission Tomography (PET)/Computerized Tomography (CT) Procedure
- Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI) Procedure
- Bone Scan Procedure
- Blood Specimen Collection Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2026 (Estimated)
- Primary completion
- Nov 30, 2028 (Estimated)
- Completion
- Nov 30, 2031 (Estimated)
- Last update posted
- Nov 9, 2026
2026 – 2031
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07925268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2026 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07925268 live on ClinicalTrials.gov.